Portal de Periódicos da CAPES

Risperidone is effective in severe hemichorea/hemiballismus

1999; Wiley; Volume: 14; Issue: 2 Linguagem: Inglês

10.1002/1531-8257(199903)14

1531-8257

Virgilio Gerald H. Evidente, Katrina Gwinn, John N. Caviness, Charles H. Adler,

Genetic Neurodegenerative Diseases

Movement DisordersVolume 14, Issue 2 p. 377-379 Clinical/Scientific Notes Risperidone is effective in severe hemichorea/hemiballismus† Virgilio Gerald H. Evidente MD, Virgilio Gerald H. Evidente MD Mayo Clinic Scottdale, Scottsdale, Arizona, U.S.A. St. Lukes Philippine Movement Disorders Center, St. Lukes Medical Center, Quezon City, PhilippinesSearch for more papers by this authorKatrina Gwinn-Hardy MD, Corresponding Author Katrina Gwinn-Hardy MD Mayo Clinic Jacksonville, Jacksonville, Florida, U.S.A.Department of Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, U.S.A.Search for more papers by this authorJohn N. Caviness MD, John N. Caviness MD Mayo Clinic Scottsdale, Scottsdale, Arizona, U.S.A.Search for more papers by this authorCharles H. Adler MD, PhD, Charles H. Adler MD, PhD Mayo Clinic Scottsdale, Scottsdale, Arizona, U.S.A.Search for more papers by this author Virgilio Gerald H. Evidente MD, Virgilio Gerald H. Evidente MD Mayo Clinic Scottdale, Scottsdale, Arizona, U.S.A. St. Lukes Philippine Movement Disorders Center, St. Lukes Medical Center, Quezon City, PhilippinesSearch for more papers by this authorKatrina Gwinn-Hardy MD, Corresponding Author Katrina Gwinn-Hardy MD Mayo Clinic Jacksonville, Jacksonville, Florida, U.S.A.Department of Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, U.S.A.Search for more papers by this authorJohn N. Caviness MD, John N. Caviness MD Mayo Clinic Scottsdale, Scottsdale, Arizona, U.S.A.Search for more papers by this authorCharles H. Adler MD, PhD, Charles H. Adler MD, PhD Mayo Clinic Scottsdale, Scottsdale, Arizona, U.S.A.Search for more papers by this author First published: 17 January 2001 https://doi.org/10.1002/1531-8257(199903)14:2 3.0.CO;2-NCitations: 10 † A videotape accompanies this article. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1Mark MH. Other choreatic disorders. In: RL Watts, WC Koller, eds. Movement Disorders. Neurologic Principles and Practice. New York, NY: McGraw-Hill, 1997: 527– 539. 2Johnson WG, Fahn S. Treatment of vascular hemiballism and hemichorea. Neurology 1977; 27: 634– 636. 3Klawans HL, Moses H, Nausieda PA, Bergen D, Weiner WJ. N Engl J Med 1976; 295: 1348– 1350. 4Livingston MG. Risperidone. Lancet 1994; 343: 457– 460. 5Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997; 12: 119– 121. 6Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69– 75. 7Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358– 362. 8Fahn S. Treatment of tardive dyskinesia: use of dopamine-depleting agents. Clin Neuropharmacol 1983; 6: 151– 158. 9Sussman AN, Tran-Nguyen LT, Neisewander JL. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur J Pharmacol 1997; 337: 157– 160. 10Dewey RB Jr, Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol 1989; 8: 862– 867. 11Sethi KD, Patel BP. Inconsistent response to divalproex sodium in hemichorea-hemiballism. Neurology 1990; 40: 1630– 1631. 12Bashir K, Manyam BV. Clozapine for the control of hemiballismus. Clin Neuropharmacol 1994; 17: 477– 480. 13Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63– 101. 14Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry 1995; 56: 484– 485. 15Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first 3 years in general use. Int Clin Psychopharmacol 1997; 12: S3– S10. 16Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207– 1213. 17Brown K, Reid A, White T, Henderson T, Hukin S. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 1998; 43: 863– 867. 18Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57– 73. Citing Literature Volume14, Issue2March 1999Pages 377-379 ReferencesRelatedInformation